The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study

Claudio Tripodo, Christian Steidl, Joanna Tajer, Bogdan Małkowski, Alessandro Broccoli, Patrizia Agati, Justyna Rybka, Lisa Argnani, Maria Teresa Sista, Francesco D'Amore, Alessandra Romano, Alessandro Levis, Luisa Stracqualursi, Stefano A Pileri, Jan Maciej Zaucha, Anna Borra, Fabio Fuligni, Waldemar Kulikowski, Edyta Subocz, Peter KamperClaudio Agostinelli, Caterina Patti, Caterina Stelitano, Francesco Merli, Luigi Rigacci, Umberto Vitolo, Pier Paolo Piccaluga, Andrea Gallamini, Stefano Fanti, Stephen Hamilton-Dutoit, Alberto Biggi, Livio Trentin, Randy D Gascoyne, Pier Luigi Zinzani

Research output: Contribution to journalArticlepeer-review

41 Citations (Scopus)

Abstract

Early-interim fluorodeoxyglucose (FDG)-PET scan after two ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) chemotherapy courses (PET-2) represents the most effective predictor of treatment outcome in classical Hodgkin's lymphoma. We aimed to assess the predictive value of PET-2 combined with tissue biomarkers in neoplastic and microenvironmental cells for this disease.
Original languageEnglish
Pages (from-to)e467-e479
Number of pages13
JournalTHE LANCET. HAEMATOLOGY
Volume3
Publication statusPublished - 2016

All Science Journal Classification (ASJC) codes

  • Hematology

Fingerprint

Dive into the research topics of 'The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study'. Together they form a unique fingerprint.

Cite this